U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07831369) titled 'VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma' on Sept. 09.
Brief Summary: The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas
Study Start Date: Sept. 04
Study Type: INTERVENTIONAL
Condition:
Glioblastoma
Astrocytoma, IDH-Mutant, Grade 4
Intervention:
DRUG: Valproic Acid (VPA)
Day 1 40mg/kg/dose PO BID and simvastatin at 40mg PO daily
DRUG: Irinoteca...